Esophageal Cancer Explained 🔥 | SCC vs Adenocarcinoma, Staging & Treatment | Omar Reda

Esophageal cancer is not one disease. Squamous cell carcinoma and adenocarcinoma arise from different backgrounds, occur in different locations, have different precursor lesions, and may require different treatment strategies. The classic clinical clue is: PROGRESSIVE DYSPHAGIA SOLIDS → LIQUIDS = MECHANICAL OBSTRUCTION UNTIL PROVEN OTHERWISE In this lecture from Gastroenterology Made Simple, we explain esophageal tumors through a practical clinical pathway: SYMPTOMS → EGD + BIOPSY → STAGING → MDT → STAGE-SPECIFIC TREATMENT This lecture covers: • Esophageal squamous cell carcinoma — ESCC • Esophageal adenocarcinoma — EAC • Major differences between ESCC and EAC • Smoking, alcohol, hot beverages, achalasia, caustic injury, and Plummer-Vinson syndrome • Barrett’s esophagus, chronic GERD, central obesity, and EAC • Progressive dysphagia from solids to liquids • Weight loss, sarcopenia, malnutrition, and aspiration • Hoarseness and recurrent laryngeal nerve involvement • Esophagorespiratory fistula • Why EGD + multiple biopsies is the diagnostic standard • What should be documented during endoscopy • Role of chromoendoscopy in early neoplasia • CT chest and abdomen for staging • FDG PET-CT for occult metastatic disease • Role of EUS in T and N staging • Why EUS should not be used as the definitive discriminator between T1a and superficial T1b lesions • Why EMR or ESD may provide the most accurate staging for superficial cancer • Bronchoscopy for tumors near the airway • AJCC 8th edition staging • T1a versus T1b disease • Early Barrett-associated adenocarcinoma • EMR versus ESD • Why visible Barrett neoplasia should be resected before ablation • ESD for superficial squamous neoplasia • When endoscopic therapy may be curative • Resectable locally advanced adenocarcinoma • Perioperative FLOT chemotherapy • CROSS chemoradiation as an alternative strategy • Adjuvant nivolumab after neoadjuvant chemoradiation and residual disease • Definitive chemoradiation for selected ESCC • Cervical esophageal SCC • Biomarker-driven metastatic treatment • HER2, PD-L1, MSI/MMR and CLDN18.2 • Immunotherapy and targeted therapy principles • SEMS for malignant dysphagia • Management of malignant tracheoesophageal fistula • Nutritional support and sarcopenia • Why SEMS should not routinely be used as a bridge to curative surgery 🧠 High-Yield Memory Rule: ESCC → usually upper/middle esophagus → smoking + alcohol + achalasia + caustic injury → precursor = squamous dysplasia EAC → usually distal esophagus / GEJ → Barrett’s + GERD + central obesity → precursor = intestinal metaplasia → dysplasia → adenocarcinoma ⚠️ Major Exam Traps: • Progressive dysphagia from solids to liquids = mechanical obstruction until proven otherwise. • Diagnosis starts with EGD + biopsy. • PET-CT looks for occult distant metastases. • EUS is mainly for locoregional staging when it will change management. • Do not rely on EUS alone to distinguish T1a from superficial T1b disease. • For superficial lesions, the resection specimen gives crucial staging information. • Barrett-associated visible neoplasia → resect first, then ablate residual Barrett’s. • Superficial ESCC → ESD is often preferred for en bloc staging. • FLOT is an important perioperative strategy for suitable resectable EAC/GEJ cancer. • CROSS remains an accepted alternative in selected patients. • Adjuvant nivolumab after residual disease applies after neoadjuvant chemoradiation + R0 surgery — not automatically after FLOT. • Do not place SEMS routinely before curative neoadjuvant therapy or surgery. 🚨 Clinical Logic: PROGRESSIVE DYSPHAGIA / ALARM FEATURES → EGD + BIOPSY → DEFINE HISTOLOGY + LOCATION SUPERFICIAL LESION → Optical assessment → EMR / ESD for definitive pathologic staging INVASIVE CANCER → CT staging → PET-CT if potentially curable → EUS ± nodal sampling when it changes management → Bronchoscopy if airway involvement suspected → MDT THEN CHOOSE: EARLY → Endoscopic therapy LOCALLY ADVANCED → Multimodality curative treatment METASTATIC → Biomarker-driven systemic therapy PALLIATIVE DYSPHAGIA → SEMS or radiotherapy according to clinical context The central message: Esophageal cancer management starts with histology and stage. Do not treat ESCC and EAC as the same disease. And in superficial cancer, accurate endoscopic resection can be both diagnostic and potentially curative. 👨‍⚕️ Lecturer: Dr. Omar Reda Abdelmaksoud 📚 Series: Gastroenterology Made Simple Deep Understanding. Clear Explanations. Better GI Care. 🌐 Official website: https://omarredaacademic.com/ 🔔 Subscribe for the next lecture in esophageal diseases and clinical gastroenterology.